ANI PHARMACEUTICALS INC shareholders approved Approval of the Amended 2022 Stock Plan.
“The vote with respect to the approval of the Amended 2022 Stock Plan was as follows: For Against Abstain Broker Non-Votes 13,806,050 1,080,387 9,388 2,030,222”
ANI PHARMACEUTICALS INC — fact timeline
Source-grounded facts extracted from ANI PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ANI PHARMACEUTICALS INC shareholders approved Approval of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers, on an advisory basis.
“The vote with respect to the approval of the frequency of future advisory votes on the compensation of the Company’s named executive officers was as follows: ONE YEAR TWO YEARS THREE YEARS Abstain Broker Non-Votes 14,412,299 4,947 467,236 11,343 2,030,222”
ANI PHARMACEUTICALS INC shareholders approved Approval of the compensation of the Company’s named executive officers, on an advisory basis.
“The vote with respect to the approval of the compensation of the Company’s named executive officers, on an advisory basis, was as follows: For Against Abstain Broker Non-Votes 13,819,988 1,058,460 17,377 2,030,222”
ANI PHARMACEUTICALS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“The vote with respect to the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: For Against Abstain 16,874,103 7,333 44,611”
ANI PHARMACEUTICALS INC shareholders approved Election of seven director nominees.
“The vote with respect to the election of each of the director nominees was as follows: Nominees For Against Abstain Broker Non-Votes Thomas Haughey 14,732,894 159,765 3,166 2,030,222 Nikhil Lalwani 14,873,796 15,198 6,831 2,030,222 Matthew J. Leonard, R.Ph. 14,743,471 149,095 3,259 2,030,222 Antonio R. Pera 14,542,012 350,649 3,164 2,030,222 Muthusamy Shanmugam 14,849,624 42,253 3,948 2,030,222 Renee P. Tannenbaum, Pharm.D. 14,063,620 829,566 2,639 2,030,222 Jeanne A. Thoma 14,565,758 327,393 2,674 2,030,222”
ANI PHARMACEUTICALS INC reported first quarter ended March 31, 2026 results: revenue $237.5 million, net income $29.5 million, EPS $1.28. Guidance raised.
“ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance • Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year • Purified Cortrophin ® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year • Quarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-year • Diluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05”
ANI PHARMACEUTICALS INC engaged Ernst & Young LLP as its auditor.
“On April 1, 2026, the Audit Committee approved the appointment of Ernst & Young LLP (“EY”), effective April 1, 2026, as the Company’s new independent registered public accounting firm for the fiscal year ended December 31, 2026.”
ANI PHARMACEUTICALS INC dismissed EisnerAmper LLP as its auditor.
“On April 1, 2026, ANI Pharmaceuticals, Inc. (the “Company”) notified EisnerAmper LLP (“EisnerAmper”) that EisnerAmper would be dismissed as the Company’s independent registered public accounting firm.”
ANI PHARMACEUTICALS INC: Amended Restated Certificate of Incorporation to increase authorized common stock from 33,333,334 to 66,000,000 shares (effective 2025-05-22).
“the amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”), providing for an increase to the number of authorized shares of common stock from 33,333,334 shares to 66,000,000 shares”
ANI PHARMACEUTICALS INC completed an acquisition involving Alimera Sciences, Inc. for $5.50 in cash, without interest and one contingent value right (closed 2024-09-16).
“or shares owned by the Company, Merger Subs or any other subsidiary of the Company or Alimera), was canceled and ceased to exist and was converted into the right to receive (i) $5.50 in cash, without interest (the “ Closing Cash Consideration ”) and (ii) one contingent value right (a “ CVR ”), which represents the right to receive the Milestone Payments (as”
ANI PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $137.4 million, net income $17.8 million, EPS $0.82. Guidance reaffirmed.
“ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82”
ANI PHARMACEUTICALS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $131.7 million, net income $0.7 million, EPS $0.04. Guidance initiated.
“ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance • Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04”
ANI PHARMACEUTICALS INC entered into Agreement with 1540700 Ontario Limited valued at $19,200,000 Canadian dollars (effective 2024-02-16).
“On February 16, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of ANI Pharmaceuticals, Inc. (“ANI”) entered into an agreement (the “Agreement”) with 1540700 Ontario Limited (“Buyer”) for the purchase and sale of ANI’s Oakville, Ontario former manufacturing facility (the “Property”) at a total purchase price of $19,200,000 Canadian dollars”
ANI PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue $131.8 million, net income $9.5 million, EPS $0.45. Guidance raised.
“Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly”
David B. Nash departed as Director at ANI PHARMACEUTICALS INC.
“On August 22, 2023, Dr. David B. Nash, M.D. informed the Board of his decision not to seek reelection as a director on the Board at the Company’s 2024 Annual Meeting of Stockholders”
Matt Leonard was appointed as Director at ANI PHARMACEUTICALS INC.
“appointed Matt Leonard to serve on the Board as a director”
ANI PHARMACEUTICALS INC reported Q2 2023 results: revenue $116.5 million, net income $5.8 million, EPS $0.29. Guidance raised.
“Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly”
ANI PHARMACEUTICALS INC shareholders approved Approval of the 2023 Stock Plan Amendment.
“Proposal No. 4 — Approval of the 2023 Stock Plan Amendment The vote with respect to the approval of the 2023 Stock Plan Amendment was as follows: For Against Abstain Broker Non-Votes 12,825,247 1,170,827 11,650 1,048,318”
ANI PHARMACEUTICALS INC shareholders approved Advisory vote to approve the compensation of the Company's named executive officers.
“Proposal No. 3 — Approval of the Say-on-Pay Proposal The vote with respect to the approval of the Company’s named executive officers, on an advisory basis, was as follows: For Against Abstain Broker Non-Votes 13,207,478 780,337 19,909 1,048,318”
ANI PHARMACEUTICALS INC shareholders approved Ratification of the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
“Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: For Against Abstain 14,959,216 95,962 864”
ANI PHARMACEUTICALS INC shareholders approved Election of eight directors to serve until the Company's 2024 Annual Meeting of Stockholders.
“Proposal No. 1 — Election of the Directors The vote with respect to the election of each of the directors was as follows: Nominees For Against Abstain Broker Non-Votes Thomas Haughey 9,898,826 4,105,256 3,642 1,048,318 Nikhil Lalwani 13,804,562 191,821 11,341 1,048,318 David B. Nash, M.D. 8,752,887 5,252,899 1,938 1,048,318 Antonio R. Pera 13,404,484 601,762 1,478 1,048,318 Muthusamy Shanmugam 13,805,957 200,160 1,607 1,048,318 Renee P. Tannenbaum, Pharm.D. 13,429,350 576,916 1,458 1,048,318 Jeanne A. Thoma 11,492,066 2,511,523 4,135 1,048,318 Patrick D. Walsh 13,757,829 248,425 1,470 1,048,318”
ANI PHARMACEUTICALS INC entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $75 million (effective 2023-05-11).
“On May 11, 2023, ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”) priced its previously announced underwritten public offering pursuant to which the Company has agreed to issue and sell an aggregate of 1,898,735 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $39.50 per share, for aggregate gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the offering (the “Offering”). Pursuant to the terms of the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between the Company and Guggenheim Securities, LLC (the “Underwriter”), the Company granted to the Underwriter a 30-day option to purchase up to an additional 284,810 shares of Common Stock.”
ANI PHARMACEUTICALS INC reported full-year 2023 results: revenue $385 million to $410 million, EPS $2.99 to $3.45. Guidance raised.
“Full Year 2023 Guidance -- Raises Company net revenue guidance to $385 million to $410 million from $360 million to $385 million; adjusted non-GAAP EBITDA guidance to $97 million to $107 million from $78 million to $88 million; adjusted non-GAAP earnings per share to $2.99 to $3.45 from $2.09 to $2.59”
ANI PHARMACEUTICALS INC reported quarter ended March 31, 2023 results: revenue $106.8 million, net income $1.0 million, EPS $0.06.
“First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06”
ANI PHARMACEUTICALS INC: Board adopted Second Amended and Restated Bylaws with clarifying amendments, updates for universal proxy rules and DGCL, including changes to quorum requirements, stockholder proposal procedures, director nomination procedures, indemnification provisions, and a forum selection clause (effective 2023-02-28).
“On February 28, 2023, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) approved the Second Amended and Restated Bylaws of the Company (the “Bylaws”), which became effective immediately.”
ANI PHARMACEUTICALS INC reported three and nine months ended September 30, 2022 results: revenue $83.8 million, net income $(9.0) million, EPS $(0.55). Guidance reaffirmed.
“ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: -- Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55)”
ANI PHARMACEUTICALS INC reported financial results for the three and nine months ended September 30, 2022.
“On November 9, 2022, ANI Pharmaceuticals, Inc. (“ANI”) issued a press release announcing its financial and operating results for the three and nine months ended September 30, 2022.”
Renee P. Tannenbaum was appointed as Director at ANI PHARMACEUTICALS INC.
“On March 19, 2022, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from eight to nine members and appointed Renee P. Tannenbaum, Pharm.D., a director of the Company, effective immediately.”
Muthusamy Shanmugam was appointed as Head of Research & Development and Chief Operating Officer–Novitium Operations at ANI PHARMACEUTICALS INC.
“On the Closing Date, in connection with the consummation of the Acquisition, the Company announced the appointment of Muthusamy Shanmugam, age 54, as Head of Research & Development and Chief Operating Officer–Novitium Operations.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.